|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2008-3-17
|
|
pubmed:abstractText |
Haplotype-mismatched CD34(+) selected allogeneic stem cell transplantation (HASCT) has been described as a therapeutic option for patients with acute myeloid leukemia. The success of this regimen is based mainly on natural killer (NK) cell-mediated antileukemia effects.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD34,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD56,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Differentiation...,
http://linkedlifedata.com/resource/pubmed/chemical/CD69 antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Fas Ligand Protein,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-DR Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-15,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Lectins, C-Type,
http://linkedlifedata.com/resource/pubmed/chemical/TNF-Related Apoptosis-Inducing...
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0301-472X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
36
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
378-89
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18261840-Adult,
pubmed-meshheading:18261840-Antigens, CD,
pubmed-meshheading:18261840-Antigens, CD34,
pubmed-meshheading:18261840-Antigens, CD56,
pubmed-meshheading:18261840-Antigens, Differentiation, T-Lymphocyte,
pubmed-meshheading:18261840-Chimerism,
pubmed-meshheading:18261840-Fas Ligand Protein,
pubmed-meshheading:18261840-Female,
pubmed-meshheading:18261840-HLA-DR Antigens,
pubmed-meshheading:18261840-Haplotypes,
pubmed-meshheading:18261840-Histocompatibility Testing,
pubmed-meshheading:18261840-Humans,
pubmed-meshheading:18261840-Immunophenotyping,
pubmed-meshheading:18261840-Interleukin-15,
pubmed-meshheading:18261840-Interleukin-2,
pubmed-meshheading:18261840-Killer Cells, Natural,
pubmed-meshheading:18261840-Lectins, C-Type,
pubmed-meshheading:18261840-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:18261840-Leukemia, Myeloid, Acute,
pubmed-meshheading:18261840-Male,
pubmed-meshheading:18261840-Middle Aged,
pubmed-meshheading:18261840-Postoperative Complications,
pubmed-meshheading:18261840-Prospective Studies,
pubmed-meshheading:18261840-Recurrence,
pubmed-meshheading:18261840-Stem Cell Transplantation,
pubmed-meshheading:18261840-TNF-Related Apoptosis-Inducing Ligand,
pubmed-meshheading:18261840-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Altered phenotype of natural killer cell subsets after haploidentical stem cell transplantation.
|
|
pubmed:affiliation |
Medizinische Klinik und Poliklinik I, Dresden, Germany.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
